RNA Key Statistics, Chart & Performance
The current stock price of RNA is 72.51 USD. In the past month the price increased by 0.89%. In the past year, price increased by 150.73%.
RNA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RNA. When comparing the yearly performance of all stocks, RNA is one of the better performing stocks in the market, outperforming 97.04% of all stocks.
RNA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RNA. RNA has a great financial health rating, but its profitability evaluates not so good.
RNA Financial Highlights
Over the last trailing twelve months RNA reported a non-GAAP Earnings per Share(EPS) of -4.18. The EPS decreased by -45.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.76% | ||
| ROE | -29.15% | ||
| Debt/Equity | 0 |
RNA Forecast & Estimates
18 analysts have analysed RNA and the average price target is 74.07 USD. This implies a price increase of 2.15% is expected in the next year compared to the current price of 72.51.
For the next year, analysts expect an EPS growth of -57.21% and a revenue growth 95.83% for RNA
RNA Ownership
RNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About RNA
Company Profile
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 391 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Company Info
AVIDITY BIOSCIENCES INC
3020 Callan Road
San Diego CALIFORNIA 92037 US
CEO: Sarah Boyce
Employees: 391
Phone: 18584017900
AVIDITY BIOSCIENCES INC / RNA FAQ
Can you describe the business of AVIDITY BIOSCIENCES INC?
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 391 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
What is the stock price of AVIDITY BIOSCIENCES INC today?
The current stock price of RNA is 72.51 USD. The price decreased by -0.12% in the last trading session.
What is the dividend status of AVIDITY BIOSCIENCES INC?
RNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of RNA stock?
RNA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does AVIDITY BIOSCIENCES INC belong to?
AVIDITY BIOSCIENCES INC (RNA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for RNA stock?
AVIDITY BIOSCIENCES INC (RNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.18).